|
FR901228A
(fr)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Système d'aimant à entrefer annulaire
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US6355476B1
(en)
|
1988-11-07 |
2002-03-12 |
Advanced Research And Technologyinc |
Nucleic acid encoding MIP-1α Lymphokine
|
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
US5061620A
(en)
|
1990-03-30 |
1991-10-29 |
Systemix, Inc. |
Human hematopoietic stem cell
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
US5199942A
(en)
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
WO1993007105A1
(en)
|
1991-10-04 |
1993-04-15 |
Iit Research Institute |
Conversion of plastic waste to useful oils
|
|
GB9125768D0
(en)
|
1991-12-04 |
1992-02-05 |
Hale Geoffrey |
Therapeutic method
|
|
EP1291360A1
(en)
|
1991-12-13 |
2003-03-12 |
Xoma Corporation |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
|
EP1498427B1
(en)
|
1992-08-21 |
2009-12-16 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
EP1005870B1
(en)
|
1992-11-13 |
2009-01-21 |
Biogen Idec Inc. |
Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
MX9504802A
(es)
|
1994-03-17 |
1997-05-31 |
Merck Patent Gmbh |
Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US5773292A
(en)
|
1995-06-05 |
1998-06-30 |
Cornell University |
Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
|
|
US7060808B1
(en)
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
|
DK0826696T3
(da)
|
1996-09-03 |
2002-09-23 |
Gsf Forschungszentrum Umwelt |
Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
|
|
HUP9904697A3
(en)
|
1996-10-11 |
2001-06-28 |
Bristol Myers Squibb Company P |
Methods and compositions for immunomodulation
|
|
EP1027439B1
(en)
*
|
1997-10-27 |
2010-03-17 |
Bac Ip B.V. |
Multivalent antigen-binding proteins
|
|
BR9907241A
(pt)
|
1998-01-26 |
2000-10-17 |
Unilever Nv |
Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
|
|
CZ121599A3
(cs)
|
1998-04-09 |
1999-10-13 |
Aventis Pharma Deutschland Gmbh |
Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
|
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
|
WO2000043507A1
(en)
|
1999-01-19 |
2000-07-27 |
Unilever Plc |
Method for producing antibody fragments
|
|
WO2001014557A1
(en)
|
1999-08-23 |
2001-03-01 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
NZ517202A
(en)
|
1999-08-24 |
2004-05-28 |
Medarex Inc |
Human CTLA-4 antibodies and their uses
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
ATE240744T1
(de)
|
1999-10-28 |
2003-06-15 |
Hofbauer Reinhold |
Verwendung von csf-1-inhibitoren
|
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
|
US20060228364A1
(en)
|
1999-12-24 |
2006-10-12 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
|
EP1261376A1
(en)
|
2000-01-27 |
2002-12-04 |
Genetics Institute, LLC |
Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
AU4328801A
(en)
|
2000-02-24 |
2001-09-03 |
Xcyte Therapies Inc |
Simultaneous stimulation and concentration of cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
EP1280826B1
(en)
|
2000-05-12 |
2007-05-02 |
Amgen Inc. |
Polypeptides for inhibiting april-mediated b- and t-cell proliferation.
|
|
CA2380443C
(en)
|
2000-05-26 |
2013-03-12 |
Ginette Dubuc |
Single-domain antigen-binding antibody fragments derived from llama antibodies
|
|
AU2001275474A1
(en)
|
2000-06-12 |
2001-12-24 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
|
CA2421751C
(en)
|
2000-09-11 |
2014-02-11 |
Donald W. Kufe |
Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
|
|
GB0100621D0
(en)
|
2001-01-10 |
2001-02-21 |
Vernalis Res Ltd |
Chemical compounds VI
|
|
CN1294148C
(zh)
*
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
|
CN1195779C
(zh)
|
2001-05-24 |
2005-04-06 |
中国科学院遗传与发育生物学研究所 |
抗人卵巢癌抗人cd3双特异性抗体
|
|
US7666414B2
(en)
|
2001-06-01 |
2010-02-23 |
Cornell Research Foundation, Inc. |
Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
|
|
JP4298498B2
(ja)
|
2001-06-13 |
2009-07-22 |
ゲンマブ エー／エス |
上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体
|
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
|
EP1433793A4
(en)
|
2001-09-13 |
2006-01-25 |
Inst Antibodies Co Ltd |
METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
|
|
ES2559002T3
(es)
|
2001-10-23 |
2016-02-10 |
Psma Development Company, L.L.C. |
Anticuerpos contra PSMA
|
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
|
JP2005289809A
(ja)
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
突然変異重鎖抗体
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
AU2003224604B2
(en)
|
2002-01-28 |
2007-06-14 |
Medarex, Inc. |
Human monoclonal antibodies to prostate specific membrane antigen (PSMA)
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
DK1507556T3
(en)
|
2002-05-02 |
2016-09-12 |
Wyeth Holdings Llc |
Calicheamicin derivative-carrier conjugates
|
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
|
EP1517921B1
(en)
*
|
2002-06-28 |
2006-06-07 |
Domantis Limited |
Dual specific ligands with increased serum half-life
|
|
WO2004010947A2
(en)
|
2002-07-30 |
2004-02-05 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1bb
|
|
PL216630B1
(pl)
|
2002-10-17 |
2014-04-30 |
Genmab As |
Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
|
|
ATE394677T1
(de)
|
2002-11-07 |
2008-05-15 |
Univ Erasmus |
Fret proben und verfahren zur erkennung aufeinander einwirkeneden moleküle
|
|
DK1578446T3
(en)
|
2002-11-07 |
2015-06-29 |
Immunogen Inc |
ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
|
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
|
EP1558647B1
(en)
|
2002-11-08 |
2015-06-10 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
|
WO2004041862A2
(en)
|
2002-11-08 |
2004-05-21 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
|
US20070178082A1
(en)
|
2002-11-08 |
2007-08-02 |
Ablynx N.V. |
Stabilized single domain antibodies
|
|
GB0228210D0
(en)
|
2002-12-03 |
2003-01-08 |
Babraham Inst |
Single chain antibodies
|
|
ES2347241T3
(es)
|
2002-12-16 |
2010-10-27 |
Genentech, Inc. |
Variantes de inmunoglobulina y sus utilizaciones.
|
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
CA2523716C
(en)
|
2003-05-31 |
2014-11-25 |
Micromet Ag |
Human anti-human cd3 binding molecules
|
|
JP2008501621A
(ja)
*
|
2003-05-31 |
2008-01-24 |
マイクロメット アクツィエン ゲゼルシャフト |
Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
|
|
US20050100543A1
(en)
|
2003-07-01 |
2005-05-12 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
|
KR101420344B1
(ko)
|
2003-07-02 |
2014-07-16 |
위니베르시따 디 제노바 |
Ｐａｎ-ｋｉｒ2ｄｌ ｎｋ-수용체 항체 및 진단 및 치료에서의 그 사용 방법
|
|
EP2292264A3
(en)
|
2003-07-24 |
2012-12-19 |
Innate Pharma |
Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
|
|
EP1660186B1
(en)
|
2003-08-18 |
2013-12-25 |
MedImmune, LLC |
Humanization of antibodies
|
|
WO2005035575A2
(en)
|
2003-08-22 |
2005-04-21 |
Medimmune, Inc. |
Humanization of antibodies
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
JP4948174B2
(ja)
|
2003-10-16 |
2012-06-06 |
マイクロメット アクツィエン ゲゼルシャフト |
多重特異的脱免疫ｃｄ３−結合物質
|
|
CN100376599C
(zh)
*
|
2004-04-01 |
2008-03-26 |
北京安波特基因工程技术有限公司 |
基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
|
|
WO2005118788A2
(en)
|
2004-05-27 |
2005-12-15 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
TW200607523A
(en)
|
2004-06-01 |
2006-03-01 |
Domantis Ltd |
Drug compositions, fusions and conjugates
|
|
JP2008512352A
(ja)
|
2004-07-17 |
2008-04-24 |
イムクローン システムズ インコーポレイティド |
新規な四価の二重特異性抗体
|
|
US20080069772A1
(en)
|
2004-08-26 |
2008-03-20 |
Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum |
Treatment of transformed or infected biological cells
|
|
EP1634603A1
(de)
|
2004-08-26 |
2006-03-15 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Behandlung von transformierten oder infizierten biologischen Zellen
|
|
FR2879605B1
(fr)
|
2004-12-16 |
2008-10-17 |
Centre Nat Rech Scient Cnrse |
Production de formats d'anticorps et applications immunologiques de ces formats
|
|
KR20130105885A
(ko)
|
2005-01-05 |
2013-09-26 |
에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. |
상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을 갖는 합성 면역글로불린 영역
|
|
WO2006072625A2
(en)
|
2005-01-06 |
2006-07-13 |
Novo Nordisk A/S |
Anti-kir combination treatments and methods
|
|
SI1836225T1
(sl)
|
2005-01-06 |
2012-06-29 |
Novo Nordisk As |
Kir vezujoäśa sredstva in postopki za njihovo rabo
|
|
WO2006105021A2
(en)
|
2005-03-25 |
2006-10-05 |
Tolerrx, Inc. |
Gitr binding molecules and uses therefor
|
|
US7833979B2
(en)
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
|
US20060252096A1
(en)
|
2005-04-26 |
2006-11-09 |
Glycofi, Inc. |
Single chain antibody with cleavable linker
|
|
ES2720160T3
(es)
|
2005-05-09 |
2019-07-18 |
Ono Pharmaceutical Co |
Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
|
|
RU2464276C2
(ru)
|
2005-05-18 |
2012-10-20 |
Аблинкс Н.В. |
Улучшенные нанотела против фактора некроза опухоли-альфа
|
|
DK2444424T3
(en)
|
2005-05-20 |
2018-12-03 |
Ablynx Nv |
IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS
|
|
EP1726650A1
(en)
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
|
EA019344B1
(ru)
|
2005-07-01 |
2014-03-31 |
МЕДАРЕКС, Эл.Эл.Си. |
Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
|
|
EP2500352A1
(en)
|
2005-08-19 |
2012-09-19 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP1940881B1
(en)
|
2005-10-11 |
2016-11-30 |
Amgen Research (Munich) GmbH |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
JP5419067B2
(ja)
|
2005-10-14 |
2014-02-19 |
イナート・ファルマ・ソシエテ・アノニム |
増殖性障害を処置するための組成物および方法
|
|
GB0521991D0
(en)
|
2005-10-28 |
2005-12-07 |
Univ Dundee |
Siglec-9 binding agents
|
|
DE602006013029D1
(de)
|
2005-11-12 |
2010-04-29 |
Lilly Co Eli |
Anti-egfr-antikörper
|
|
US8623356B2
(en)
|
2005-11-29 |
2014-01-07 |
The University Of Sydney |
Demibodies: dimerization-activated therapeutic agents
|
|
US7498142B2
(en)
|
2006-01-31 |
2009-03-03 |
Yeda Research And Development Co., Ltd. |
Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
|
|
WO2007115230A2
(en)
|
2006-03-30 |
2007-10-11 |
University Of Medicine And Dentistry Of New Jersey |
A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells
|
|
CA2647282A1
(en)
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
|
US20070269422A1
(en)
|
2006-05-17 |
2007-11-22 |
Ablynx N.V. |
Serum albumin binding proteins with long half-lives
|
|
AU2007285695B2
(en)
|
2006-08-18 |
2012-05-24 |
Ablynx N.V. |
Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
|
|
EP2069402A2
(en)
|
2006-09-08 |
2009-06-17 |
Ablynx N.V. |
Serum albumin binding proteins with long half-lives
|
|
CN101557817A
(zh)
|
2006-09-14 |
2009-10-14 |
人类基因科学公司 |
清蛋白融合蛋白
|
|
US20100166734A1
(en)
|
2006-12-20 |
2010-07-01 |
Edward Dolk |
Oral delivery of polypeptides
|
|
CN101578113B
(zh)
|
2007-01-11 |
2015-04-22 |
诺和诺德公司 |
抗-kir抗体、制剂及其应用
|
|
AU2008234019B2
(en)
*
|
2007-04-03 |
2014-05-29 |
Amgen Research (Munich) Gmbh |
Cross-species-specific bispecific binders
|
|
RU2769948C2
(ru)
|
2007-04-03 |
2022-04-11 |
Эмджен Рисерч (Мьюник) Гмбх |
CD3-Эпсилон-связывающий домен с межвидовой специфичностью
|
|
JP2008278814A
(ja)
|
2007-05-11 |
2008-11-20 |
Igaku Seibutsugaku Kenkyusho:Kk |
アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
|
|
AU2008252853B2
(en)
|
2007-05-24 |
2011-12-01 |
Ablynx N.V. |
Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
|
|
DK2176298T3
(en)
|
2007-05-30 |
2018-02-12 |
Xencor Inc |
Methods and compositions for inhibiting CD32B-expressing cells
|
|
JP5191537B2
(ja)
|
2007-06-18 |
2013-05-08 |
エム・エス・ディー・オス・ベー・フェー |
ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
|
|
EP2014680A1
(en)
|
2007-07-10 |
2009-01-14 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
|
|
CA2693677C
(en)
|
2007-07-12 |
2018-02-13 |
Tolerx, Inc. |
Combination therapies employing gitr binding molecules
|
|
EP2487190A3
(en)
|
2007-07-13 |
2012-11-14 |
Bac Ip B.V. |
Single-domain antigen-binding proteins that bind mammalian IgG
|
|
CA3128656A1
(en)
|
2007-08-22 |
2009-02-26 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
|
EP2195342A1
(en)
|
2007-09-07 |
2010-06-16 |
Ablynx N.V. |
Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
|
|
US7982016B2
(en)
*
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
|
JP5592792B2
(ja)
|
2007-09-26 |
2014-09-17 |
ユセベ ファルマ ソシエテ アノニム |
二重特異性抗体の融合体
|
|
CN101952317B
(zh)
|
2008-01-24 |
2015-07-22 |
诺沃-诺迪斯克有限公司 |
人化抗-人nkg2a单克隆抗体
|
|
EP2242773B1
(en)
|
2008-02-11 |
2017-06-14 |
Cure Tech Ltd. |
Monoclonal antibodies for tumor treatment
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
ES2713864T3
(es)
|
2008-06-05 |
2019-05-24 |
Ablynx Nv |
Secuencias de aminoácidos dirigidas contra proteínas de la envuelta de un virus y polipéptidos que comprenden las mismas para el tratamiento de enfermedades virales
|
|
US20100122358A1
(en)
|
2008-06-06 |
2010-05-13 |
Crescendo Biologics Limited |
H-Chain-only antibodies
|
|
WO2010003118A1
(en)
|
2008-07-02 |
2010-01-07 |
Trubion Pharmaceuticals, Inc. |
Tgf-b antagonist multi-target binding proteins
|
|
US8444976B2
(en)
|
2008-07-02 |
2013-05-21 |
Argen-X B.V. |
Antigen binding polypeptides
|
|
DE102008036127A1
(de)
|
2008-08-01 |
2010-02-04 |
Emitec Gesellschaft Für Emissionstechnologie Mbh |
Verfahren zum Betrieb einer Abgasanlage mit Lambda-Regelung
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
RS54233B1
(sr)
|
2008-08-25 |
2015-12-31 |
Amplimmune Inc. |
Kompozicije pd-1 antagonista i postupci za njihovu primenu
|
|
EP2328920A2
(en)
|
2008-08-25 |
2011-06-08 |
Amplimmune, Inc. |
Targeted costimulatory polypeptides and methods of use to treat cancer
|
|
EP3106468A1
(en)
|
2008-10-01 |
2016-12-21 |
Amgen Research (Munich) GmbH |
Cross-species-specific psmaxcd3 bispecific single chain antibody
|
|
AU2009299794B2
(en)
|
2008-10-01 |
2015-08-13 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
|
AU2009299793B2
(en)
|
2008-10-01 |
2016-03-10 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibodies with specificity for high molecular weight target antigens
|
|
EP2337798A4
(en)
|
2008-10-14 |
2012-10-24 |
Ca Nat Research Council |
SPECIFIC ANTIBODIES OF THE ASB
|
|
US8709411B2
(en)
|
2008-12-05 |
2014-04-29 |
Novo Nordisk A/S |
Combination therapy to enhance NK cell mediated cytotoxicity
|
|
US20100189727A1
(en)
|
2008-12-08 |
2010-07-29 |
Tegopharm Corporation |
Masking Ligands For Reversible Inhibition Of Multivalent Compounds
|
|
HUE065752T2
(hu)
|
2008-12-09 |
2024-06-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
|
|
US9345787B2
(en)
|
2008-12-22 |
2016-05-24 |
Targovax Oy |
Adenoviral vectors and methods and uses related thereto
|
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
|
EP2210902A1
(en)
|
2009-01-14 |
2010-07-28 |
TcL Pharma |
Recombinant monovalent antibodies
|
|
ES2629337T3
(es)
|
2009-02-09 |
2017-08-08 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
|
|
SG173705A1
(en)
|
2009-03-05 |
2011-09-29 |
Abbott Lab |
Il-17 binding proteins
|
|
RU2595409C2
(ru)
|
2009-09-03 |
2016-08-27 |
Мерк Шарп И Доум Корп., |
Анти-gitr-антитела
|
|
UY32917A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Moléculas de unión a dll-4
|
|
WO2011051327A2
(en)
|
2009-10-30 |
2011-05-05 |
Novartis Ag |
Small antibody-like single chain proteins
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
MX2012006406A
(es)
*
|
2009-12-04 |
2012-07-25 |
Genentech Inc |
Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
|
|
EP2332994A1
(en)
|
2009-12-09 |
2011-06-15 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Trispecific therapeutics against acute myeloid leukaemia
|
|
AU2010329934B2
(en)
|
2009-12-10 |
2015-05-14 |
F. Hoffmann-La Roche Ag |
Antibodies binding preferentially human CSF1R extracellular domain 4 and their use
|
|
WO2011079283A1
(en)
|
2009-12-23 |
2011-06-30 |
Bioalliance C.V. |
Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
|
|
SG181952A1
(en)
|
2009-12-29 |
2012-07-30 |
Emergent Product Dev Seattle |
Heterodimer binding proteins and uses thereof
|
|
GB2476681B
(en)
|
2010-01-04 |
2012-04-04 |
Argen X Bv |
Humanized camelid VH, VK and VL immunoglobulin domains
|
|
LT2530091T
(lt)
|
2010-01-29 |
2018-06-11 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-dll3 antikūnas
|
|
CA2789071C
(en)
|
2010-03-05 |
2018-03-27 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
|
MX2012010014A
(es)
|
2010-03-05 |
2012-09-21 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humano y sus usos.
|
|
WO2011119484A1
(en)
|
2010-03-23 |
2011-09-29 |
Iogenetics, Llc |
Bioinformatic processes for determination of peptide binding
|
|
US8937164B2
(en)
|
2010-03-26 |
2015-01-20 |
Ablynx N.V. |
Biological materials related to CXCR7
|
|
US9556273B2
(en)
|
2010-03-29 |
2017-01-31 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
|
|
MX355418B
(es)
|
2010-05-04 |
2018-04-18 |
Five Prime Therapeutics Inc |
Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
|
|
ES2682078T3
(es)
|
2010-06-11 |
2018-09-18 |
Kyowa Hakko Kirin Co., Ltd. |
Anticuerpo anti-TIM-3
|
|
PL391627A1
(pl)
|
2010-06-25 |
2012-01-02 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Przeciwnowotworowe białko fuzyjne
|
|
KR102810907B1
(ko)
|
2010-07-16 |
2025-05-21 |
아디맵 엘엘씨 |
항체 라이브러리
|
|
US8900590B2
(en)
|
2010-08-12 |
2014-12-02 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
|
RU2013110875A
(ru)
|
2010-08-24 |
2014-09-27 |
Ф.Хоффманн-Ля Рош Аг |
БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
|
|
RU2013110876A
(ru)
|
2010-08-24 |
2014-09-27 |
Рош Гликарт Аг |
Активируемые биспецифические антитела
|
|
WO2012042026A1
(en)
|
2010-09-30 |
2012-04-05 |
Ablynx Nv |
Biological materials related to c-met
|
|
EP2640750A1
(en)
|
2010-11-16 |
2013-09-25 |
Boehringer Ingelheim International GmbH |
Agents and methods for treating diseases that correlate with bcma expression
|
|
CA2818684C
(en)
|
2010-11-22 |
2023-02-21 |
Innate Pharma Sa |
Nk cell modulating treatments and methods for treatment of hematological malignancies
|
|
MX360254B
(es)
|
2011-03-10 |
2018-10-26 |
Pfizer |
Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
|
|
EP2684953B1
(en)
|
2011-03-11 |
2017-06-28 |
Kaneka Corporation |
Modified aminotransferase, gene thereof, and method for producing optically active amino compound using same
|
|
CN106039306A
(zh)
|
2011-03-30 |
2016-10-26 |
埃博灵克斯股份有限公司 |
使用针对TNFα的单结构域抗体治疗免疫病症的方法
|
|
ES2872077T3
(es)
|
2011-04-08 |
2021-11-02 |
Us Health |
Receptor de antígenos quiméricos anti-variante III del receptor de factor de crecimiento epidérmico y uso de los mismos para el tratamiento de cáncer
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
AU2012245116A1
(en)
*
|
2011-04-20 |
2013-11-07 |
Genmab A/S |
Bispecific antibodies against HER2 and CD3
|
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
WO2012162068A2
(en)
|
2011-05-21 |
2012-11-29 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
|
TWI560200B
(en)
|
2011-05-25 |
2016-12-01 |
Innate Pharma Sa |
Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
|
|
SG194176A1
(en)
|
2011-05-27 |
2013-12-30 |
Glaxo Group Ltd |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
EP3466972B1
(en)
|
2011-06-23 |
2026-03-04 |
Ablynx NV |
Serum albumin binding proteins
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
WO2013036130A1
(en)
|
2011-09-09 |
2013-03-14 |
Universiteit Utrecht Holding B.V. |
Broadly neutralizing vhh against hiv-1
|
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
|
AU2012311451B2
(en)
|
2011-09-23 |
2017-08-10 |
Universitat Stuttgart |
Serum half-life extension using immunoglobulin binding domains
|
|
CN106046161B
(zh)
|
2011-09-30 |
2019-09-13 |
埃博灵克斯股份有限公司 |
与C-Met相关的生物物质
|
|
ES2546317T3
(es)
|
2011-10-11 |
2015-09-22 |
Ucb Biopharma Sprl |
Derivados de 2-oxo-piperidinilo
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
KR101981873B1
(ko)
|
2011-11-28 |
2019-05-23 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
US10023643B2
(en)
|
2011-12-15 |
2018-07-17 |
Hoffmann-La Roche Inc. |
Antibodies against human CSF-1R and uses thereof
|
|
BR112014014181A2
(pt)
|
2011-12-16 |
2017-06-13 |
Oncology Inst Of Southern Switzerland |
combinação de ozogamicina inotuzumab e torisel para o tratamento de câncer
|
|
EP2793918B1
(en)
|
2011-12-19 |
2019-09-11 |
The Rockefeller University |
Hdc-sign binding peptides
|
|
HUE035207T2
(en)
|
2012-01-13 |
2018-05-02 |
Univ Wuerzburg J Maximilians |
Dual antigen-induced bipartite functional complementation
|
|
AU2013201422B2
(en)
|
2012-01-23 |
2015-04-09 |
Ablynx Nv |
Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors
|
|
EP2812355A4
(en)
|
2012-02-06 |
2016-03-02 |
Hoffmann La Roche |
COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS
|
|
MX2014010183A
(es)
|
2012-02-22 |
2015-03-20 |
Univ Pennsylvania |
Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer.
|
|
EP3093294A1
(en)
|
2012-02-24 |
2016-11-16 |
Stemcentrx, Inc. |
Dll3 modulators and methods of use
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
MX353382B
(es)
|
2012-03-01 |
2018-01-10 |
Amgen Res Munich Gmbh |
Moleculas de union polipeptido de larga duracion.
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
CN107266574A
(zh)
|
2012-03-30 |
2017-10-20 |
拜尔健康护理有限责任公司 |
蛋白酶调节的抗体
|
|
US10202452B2
(en)
|
2012-04-20 |
2019-02-12 |
Aptevo Research And Development Llc |
CD3 binding polypeptides
|
|
MX2014013041A
(es)
|
2012-04-27 |
2015-03-19 |
Cytomx Therapeutics Inc |
Anticuerpos activables que se ligan al receptor del factor de crecimiento epidermico y metodos de uso de los mismos.
|
|
JP2015517490A
(ja)
|
2012-05-11 |
2015-06-22 |
ファイブ プライム セラピューティックス インコーポレイテッド |
コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法
|
|
US9212224B2
(en)
|
2012-05-15 |
2015-12-15 |
Bristol-Myers Squibb Company |
Antibodies that bind PD-L1 and uses thereof
|
|
KR101566538B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Ｔｈ17 세포 전환용 에피토프 및 이의 용도
|
|
US9856314B2
(en)
|
2012-06-22 |
2018-01-02 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and methods of using the same
|
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
US20140154253A1
(en)
|
2012-07-13 |
2014-06-05 |
Zymeworks Inc. |
Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
|
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
SG10201906328RA
(en)
|
2012-08-31 |
2019-08-27 |
Five Prime Therapeutics Inc |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
AU2013310839B2
(en)
|
2012-08-31 |
2017-06-01 |
Argenx Bvba |
Highly diverse combinatorial antibody libraries
|
|
KR101963231B1
(ko)
|
2012-09-11 |
2019-03-28 |
삼성전자주식회사 |
이중특이 항체의 제작을 위한 단백질 복합체 및 이를 이용한 이중특이 항체 제조 방법
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
JP6307085B2
(ja)
|
2012-09-27 |
2018-04-04 |
ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ ｏｆ Ａｍｅｒｉｃａ，ａｓ ｒｅｐｒｅｓｅｎｔｅｄ ｂｙ ｔｈｅ Ｓｅｃｒｅｔａｒｙ，Ｄｅｐａｒｔｍｅｎｔ ｏｆ Ｈｅａｌｔｈ ａｎｄ Ｈｕｍａｎ Ｓｅｒｖｉｃｅｓ |
メソテリン抗体および強力な抗腫瘍活性を惹起するための方法
|
|
KR102130865B1
(ko)
|
2012-10-02 |
2020-08-05 |
브리스톨-마이어스 스큅 컴퍼니 |
암을 치료하기 위한 항-kir 항체와 항-pd-1 항체의 조합물
|
|
CN104780940B
(zh)
*
|
2012-11-06 |
2017-11-07 |
拜耳制药股份公司 |
用于双特异性t细胞衔接体(bites)的制剂
|
|
US9243058B2
(en)
|
2012-12-07 |
2016-01-26 |
Amgen, Inc. |
BCMA antigen binding proteins
|
|
US9969789B2
(en)
|
2012-12-17 |
2018-05-15 |
Trillium Therapeutics Inc. |
Treatment of CD47+ disease cells with SIRP alpha-Fc fusions
|
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
|
RU2019109456A
(ru)
|
2013-02-22 |
2019-04-10 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Новые конъюгаты антител и их применения
|
|
BR112015020235A2
(pt)
|
2013-02-28 |
2017-10-10 |
Univ Edinburgh |
fragmento biologicamente ativo de proteína csf-1 ou um seu homólogo, ácido nucléico, proteína de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de realização da proteína de fusão do primeiro aspeto da invenção, composição, utilização de uma proteína de fusão, método de tratamento para um indivíduo sofrendo de cancro do fígado e que irá ser submetido a cirurgia, método de tratamento para um indivíduo que irá ser submetido a cirurgia de transplante de fígado, e, kit
|
|
US20160015749A1
(en)
|
2013-03-05 |
2016-01-21 |
Baylor College Of Medicine |
Engager cells for immunotherapy
|
|
WO2014160030A2
(en)
|
2013-03-13 |
2014-10-02 |
Health Research, Inc. |
Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
|
|
US9725520B2
(en)
|
2013-03-14 |
2017-08-08 |
The Board Of Regents Of The University Of Texas System |
HER3 specific monoclonal antibodies for diagnostic and therapeutic use
|
|
US10351626B2
(en)
|
2013-03-14 |
2019-07-16 |
The Scripps Research Institute |
Targeting agent antibody conjugates and uses thereof
|
|
EP2970484B2
(en)
*
|
2013-03-15 |
2022-09-21 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
SI2970449T1
(sl)
|
2013-03-15 |
2019-11-29 |
Amgen Res Munich Gmbh |
Enoverižne vezavne molekule, ki vsebujejo N-terminalni ABP
|
|
US20140308285A1
(en)
|
2013-03-15 |
2014-10-16 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
CN105377297B
(zh)
|
2013-05-28 |
2019-09-17 |
Dcb-美国有限责任公司 |
用于蛋白质药物失活的抗体锁扣
|
|
DK3406633T3
(da)
|
2013-07-25 |
2022-03-28 |
Cytomx Therapeutics Inc |
Multispecifikke antistoffer, multispecifikke aktiverbare antistoffer og fremgangsmåder til anvendelse heraf
|
|
EA035550B1
(ru)
|
2013-08-01 |
2020-07-06 |
Юниверсите Католик Де Лувэн |
АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С КОМПЛЕКСОМ hGARP/TGF-B1, И ИХ ПРИМЕНЕНИЕ
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
KR20160047567A
(ko)
|
2013-08-28 |
2016-05-02 |
스템센트알엑스 인코포레이티드 |
조작된 항-dll3 접합체 및 사용 방법
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
JP6623353B2
(ja)
|
2013-09-13 |
2019-12-25 |
ベイジーン スウィッツァーランド ゲーエムベーハー |
抗ｐｄ−１抗体並びにその治療及び診断のための使用
|
|
SI3508502T1
(sl)
|
2013-09-20 |
2023-07-31 |
Bristol-Myers Squibb Company |
Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev
|
|
EP3049520B1
(en)
|
2013-09-24 |
2017-07-05 |
University of Washington through its Center for Commercialization |
Desmoglein 2 (dsg2) binding proteins and uses therefor
|
|
PT3049439T
(pt)
|
2013-09-26 |
2020-03-31 |
Ablynx Nv |
Nanocorpos biespecíficos
|
|
US9126984B2
(en)
|
2013-11-08 |
2015-09-08 |
Iteos Therapeutics |
4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
|
|
US20160263087A1
(en)
|
2013-11-08 |
2016-09-15 |
Iteos Therapeutics |
Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
|
|
EP3082802B1
(en)
|
2013-12-03 |
2020-02-26 |
Iomet Pharma Ltd. |
Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use
|
|
NZ720353A
(en)
|
2013-12-30 |
2019-12-20 |
Epimab Biotherapeutics Inc |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
EP3105225A1
(en)
|
2014-02-12 |
2016-12-21 |
iTeos Therapeutics |
Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
|
|
KR20170008202A
(ko)
|
2014-02-21 |
2017-01-23 |
애브비 스템센트알엑스 엘엘씨 |
흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
|
|
JP2017513818A
(ja)
|
2014-03-15 |
2017-06-01 |
ノバルティス アーゲー |
キメラ抗原受容体を使用する癌の処置
|
|
WO2015140717A1
(en)
|
2014-03-18 |
2015-09-24 |
Iteos Therapeutics |
Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
|
|
EP3122779B1
(en)
|
2014-03-24 |
2019-05-22 |
Cancer Research Technology Limited |
Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof
|
|
JPWO2015146437A1
(ja)
|
2014-03-25 |
2017-04-13 |
国立大学法人東北大学 |
高機能性ＩｇＧ２型二重特異性抗体
|
|
PT3126381T
(pt)
|
2014-04-01 |
2019-04-18 |
Ganymed Pharmaceuticals Ag |
Imunorrecetores e epítopos de células t específicos da claudina-6
|
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
RS60878B1
(sr)
|
2014-04-04 |
2020-11-30 |
Iomet Pharma Ltd |
Derivati indola za upotrebu u medicini
|
|
SG10201913507SA
(en)
|
2014-05-02 |
2020-02-27 |
Momenta Pharmaceuticals Inc |
Compositions and methods related to engineered fc constructs
|
|
WO2015173764A1
(en)
|
2014-05-15 |
2015-11-19 |
Iteos Therapeutics |
Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors
|
|
AU2015266958A1
(en)
|
2014-05-28 |
2016-12-08 |
Agenus Inc. |
Anti-GITR antibodies and methods of use thereof
|
|
TWI742423B
(zh)
|
2014-05-29 |
2021-10-11 |
美商宏觀基因股份有限公司 |
特異性結合多種癌症抗原的三特異性結合分子和其使用方法
|
|
JP6449338B2
(ja)
|
2014-06-06 |
2019-01-09 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
|
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
US10174095B2
(en)
|
2014-07-21 |
2019-01-08 |
Novartis Ag |
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
|
|
AU2015292406B2
(en)
|
2014-07-25 |
2021-03-11 |
Cytomx Therapeutics, Inc |
Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
|
|
MX384418B
(es)
|
2014-07-31 |
2025-03-14 |
Amgen Res Munich Gmbh |
Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido.
|
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
GB201414730D0
(en)
|
2014-08-19 |
2014-10-01 |
Tpp Global Dev Ltd |
Pharmaceutical compound
|
|
RU2017105425A
(ru)
|
2014-08-28 |
2018-09-28 |
Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк |
Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины
|
|
JO3568B1
(ar)
|
2014-09-05 |
2020-07-05 |
Janssen Pharmaceutica Nv |
عوامل ربط cd123 واستخداماتها
|
|
CN105471609B
(zh)
|
2014-09-05 |
2019-04-05 |
华为技术有限公司 |
一种用于配置业务的方法和装置
|
|
WO2016038064A1
(en)
|
2014-09-10 |
2016-03-17 |
Innate Pharma |
Cross reactive siglec antibodies
|
|
WO2016041947A1
(en)
|
2014-09-16 |
2016-03-24 |
Innate Pharma |
Treatment regimens using anti-nkg2a antibodies
|
|
MX2017003847A
(es)
|
2014-09-25 |
2017-12-15 |
Amgen Inc |
Proteinas biespecificas activables por proteasas.
|
|
MX2017004603A
(es)
|
2014-10-07 |
2017-06-30 |
Cellectis |
Metodo para modular actividad de celulas inmunes inducidas por car.
|
|
GB201419579D0
(en)
|
2014-11-03 |
2014-12-17 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
AU2015341913B2
(en)
|
2014-11-03 |
2020-07-16 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
MX385320B
(es)
|
2014-11-10 |
2025-03-18 |
Medimmune Ltd |
Moléculas de unión específicas para grupo de diferenciación 73 (cd73) y usos de las mismas.
|
|
BR112017011166A2
(pt)
|
2014-11-26 |
2018-02-27 |
Xencor, Inc. |
anticorpos heterodiméricos que se ligam a cd3 e cd38
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
US11001625B2
(en)
|
2014-12-10 |
2021-05-11 |
Tufts University |
VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
|
|
EP3237449A2
(en)
*
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
US20180318417A1
(en)
|
2015-01-14 |
2018-11-08 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
|
WO2016125017A1
(en)
|
2015-02-03 |
2016-08-11 |
Universite Catholique De Louvain |
Anti-garp protein and uses thereof
|
|
PH12017501216B1
(en)
|
2015-02-05 |
2023-05-24 |
Janssen Vaccines And Prevention B V |
Binding molecules directed against influenza hemagglutinin and uses thereof
|
|
EP3256495A4
(en)
|
2015-02-11 |
2018-09-19 |
Aptevo Research and Development LLC |
Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
|
|
EP3259597B1
(en)
|
2015-02-19 |
2022-04-06 |
Compugen Ltd. |
Pvrig polypeptides and methods of treatment
|
|
US10227408B2
(en)
|
2015-02-19 |
2019-03-12 |
Compugen Ltd. |
Anti-PVRIG antibodies and methods of use
|
|
MA41613A
(fr)
|
2015-02-23 |
2018-01-02 |
Abbvie Stemcentrx Llc |
Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
|
|
JP6775516B2
(ja)
|
2015-03-17 |
2020-10-28 |
ファイザー・インク |
新奇な３−インドール置換誘導体、医薬組成物、および使用方法
|
|
EP3286320A2
(en)
|
2015-04-22 |
2018-02-28 |
Agbiome, Inc. |
Insecticidal genes and methods of use
|
|
HK1250997A1
(zh)
|
2015-05-01 |
2019-01-18 |
基因泰克公司 |
掩蔽抗cd3抗体和使用方法
|
|
CA2985125A1
(en)
|
2015-05-06 |
2016-11-10 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
|
EP3296395B2
(en)
|
2015-05-13 |
2024-06-19 |
Chugai Seiyaku Kabushiki Kaisha |
Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion
|
|
PL3294319T3
(pl)
|
2015-05-13 |
2024-10-07 |
Ablynx Nv |
Polipeptydy rekrutujące komórki t na podstawie reaktywności cd3
|
|
TW201705955A
(zh)
|
2015-05-14 |
2017-02-16 |
輝瑞大藥廠 |
包含吡咯啶－２，５－二酮ｉｄｏ１抑制劑及抗－ｐｄ１／抗－ｐｄ－ｌ１抗體之組合療法
|
|
JP6867302B2
(ja)
|
2015-05-21 |
2021-04-28 |
フル スペクトラム ジェネティクス， インコーポレイテッド |
タンパク質の特徴を改善する方法
|
|
ES2889906T3
(es)
|
2015-05-21 |
2022-01-14 |
Harpoon Therapeutics Inc |
Proteínas de unión triespecíficas y usos médicos
|
|
BR112017025929A2
(pt)
|
2015-06-03 |
2018-08-14 |
Agbiome Inc |
genes pesticidas e métodos de uso
|
|
DK3313874T3
(da)
|
2015-06-26 |
2021-05-03 |
Univ Southern California |
Maskering af kimære antigen-receptor t-celler til tumorspecifik aktivering
|
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
ES2693596T3
(es)
|
2015-07-10 |
2018-12-12 |
Merus N.V. |
Anticuerpo que se une a CD3 humano
|
|
WO2017008169A1
(en)
|
2015-07-15 |
2017-01-19 |
Zymeworks Inc. |
Drug-conjugated bi-specific antigen-binding constructs
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究（慕尼黑）公司 |
Dll3及cd3抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
EP3670535A1
(en)
|
2015-08-03 |
2020-06-24 |
EngMab Sàrl |
Monoclonal antibodies against bcma
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
JP2018527336A
(ja)
|
2015-08-10 |
2018-09-20 |
ファイザー・インク |
３−インドール置換誘導体、医薬組成物、および使用方法
|
|
WO2017025698A1
(en)
|
2015-08-11 |
2017-02-16 |
Queen Mary University Of London |
Bispecific, cleavable antibodies
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
TWI811023B
(zh)
|
2015-08-17 |
2023-08-01 |
美商健生生物科技公司 |
抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途
|
|
JP2018529656A
(ja)
|
2015-08-20 |
2018-10-11 |
アッヴィ・ステムセントルクス・エル・エル・シー |
抗ｄｌｌ３抗体薬物コンジュゲートおよび使用方法
|
|
CN106519037B
(zh)
|
2015-09-11 |
2019-07-23 |
科济生物医药（上海）有限公司 |
可活化的嵌合受体
|
|
PT3354729T
(pt)
|
2015-09-24 |
2024-04-11 |
Daiichi Sankyo Co Ltd |
Anticorpo anti-garp
|
|
CN116003596A
(zh)
|
2015-10-29 |
2023-04-25 |
艾利妥 |
抗siglec-9抗体及其使用方法
|
|
CA3004299A1
(en)
|
2015-11-05 |
2017-05-11 |
City Of Hope |
Methods for preparing cells for adoptive t cell therapy
|
|
PT3377103T
(pt)
|
2015-11-19 |
2021-05-26 |
Revitope Ltd |
Complementação de fragmento de anticorpo funcional para um sistema de dois componentes para exterminação redirecionada de células indesejadas
|
|
CN121154828A
(zh)
|
2015-11-19 |
2025-12-19 |
豪夫迈·罗氏有限公司 |
使用b-raf抑制剂和免疫检查点抑制剂治疗癌症的方法
|
|
IL259576B
(en)
|
2015-12-04 |
2022-09-01 |
Novartis Ag |
grna molecule containing tracr and crrna, pharmaceutical composition containing it and method for preparing cells for immunotherapy
|
|
CA3011092A1
(en)
|
2016-01-12 |
2017-07-20 |
Palleon Pharmaceuticals Inc. |
Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
|
|
US9624185B1
(en)
|
2016-01-20 |
2017-04-18 |
Yong Xu |
Method for preparing IDO inhibitor epacadostat
|
|
US10093694B2
(en)
|
2016-02-03 |
2018-10-09 |
Guangzhou Kangrui Biological Pharmaceutical Technology Co, Ltd. |
Compounds for treating eye disorders or diseases
|
|
IL313507A
(en)
|
2016-02-03 |
2024-08-01 |
Amgen Res Munich Gmbh |
Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
|
|
AU2017229687A1
(en)
|
2016-03-08 |
2018-09-20 |
Takeda Pharmaceutical Company Limited |
Inducible binding proteins and methods of use
|
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
|
SG11201808085WA
(en)
|
2016-03-22 |
2018-10-30 |
Hoffmann La Roche |
Protease-activated t cell bispecific molecules
|
|
WO2017173091A1
(en)
|
2016-03-30 |
2017-10-05 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
CA3024723A1
(en)
|
2016-05-20 |
2017-11-23 |
Robert B. Dubridge |
Single domain serum albumin binding protein
|
|
PT3461261T
(pt)
|
2016-05-20 |
2025-07-31 |
Harpoon Therapeutics Inc |
Proteínas de ligação ao cd3 de fragmento variável de cadeia única
|
|
CA3024679A1
(en)
|
2016-05-20 |
2017-11-23 |
Abbvie Stemcentrx Llc |
Anti-dll3 drug conjugates for treating tumors at risk of neuroendocrine transition
|
|
WO2017210443A1
(en)
|
2016-06-01 |
2017-12-07 |
Xencor, Inc. |
Bispecific antibodies that bind cd123 and cd3
|
|
TWI640536B
(zh)
|
2016-06-20 |
2018-11-11 |
克馬伯有限公司 |
抗體
|
|
WO2018017864A2
(en)
|
2016-07-20 |
2018-01-25 |
Oncomed Pharmaceuticals, Inc. |
Pvrig-binding agents and uses thereof
|
|
US20190309092A1
(en)
|
2016-07-21 |
2019-10-10 |
Development Center For Biotechnology |
Modified antigen-binding fab fragments and antigen-binding molecules comprising the same
|
|
CA3032498A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
KR20190035863A
(ko)
|
2016-08-05 |
2019-04-03 |
알라코스 인크. |
암 치료를 위한 항Siglec-7 항체
|
|
US11324744B2
(en)
|
2016-08-08 |
2022-05-10 |
Acetylon Pharmaceuticals Inc. |
Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and CD20 inhibitory antibodies
|
|
CN112274637A
(zh)
|
2016-08-17 |
2021-01-29 |
康姆普根有限公司 |
抗tigit抗体、抗pvrig抗体及其组合
|
|
US20190218294A1
(en)
|
2016-09-09 |
2019-07-18 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
|
|
WO2018071777A1
(en)
|
2016-10-14 |
2018-04-19 |
Harpoon Therapeutics, Inc. |
Innate immune cell trispecific binding proteins and methods of use
|
|
EP3526246A1
(en)
|
2016-10-17 |
2019-08-21 |
Vetoquinol SA |
Modified antibody constant region
|
|
WO2018075359A1
(en)
|
2016-10-18 |
2018-04-26 |
Boger Henry William |
Wireless power transfer for process control
|
|
BR112019008861A2
(pt)
|
2016-11-01 |
2019-07-09 |
Tesaro, Inc. |
anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3)
|
|
US11124577B2
(en)
|
2016-11-02 |
2021-09-21 |
Engmab Sàrl |
Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
|
|
KR20190087539A
(ko)
|
2016-11-23 |
2019-07-24 |
하푼 테라퓨틱스, 인크. |
Psma 표적화 삼중특이성 단백질 및 사용 방법
|
|
EP3544997A4
(en)
|
2016-11-23 |
2020-07-01 |
Harpoon Therapeutics, Inc. |
PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN
|
|
EP3551659A1
(en)
|
2016-12-08 |
2019-10-16 |
Eli Lilly and Company |
Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies
|
|
JOP20190133A1
(ar)
|
2016-12-08 |
2019-06-02 |
Innovent Biologics Suzhou Co Ltd |
أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
|
|
CA3046432A1
(en)
|
2016-12-13 |
2018-06-21 |
Astellas Pharma Inc. |
Anti-human cd73 antibody
|
|
WO2018115859A1
(en)
|
2016-12-20 |
2018-06-28 |
Kymab Limited |
Multispecific antibody with combination therapy for immuno-oncology
|
|
NZ754994A
(en)
|
2016-12-22 |
2022-12-23 |
Amgen Inc |
Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
|
|
WO2018136725A1
(en)
|
2017-01-19 |
2018-07-26 |
Harpoon Therapeutics, Inc. |
Innate immune cell inducible binding proteins and methods of use
|
|
WO2018133877A1
(zh)
|
2017-01-23 |
2018-07-26 |
科济生物医药（上海）有限公司 |
靶向bcma的抗体及其应用
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
WO2018160671A1
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Targeted checkpoint inhibitors and methods of use
|
|
JP2020511130A
(ja)
|
2017-03-09 |
2020-04-16 |
サイトメックス セラピューティクス インコーポレイテッド |
Ｃｄ１４７抗体、活性化可能ｃｄ１４７抗体、ならびにその作製および使用の方法
|
|
WO2018183366A1
(en)
|
2017-03-28 |
2018-10-04 |
Syndax Pharmaceuticals, Inc. |
Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
|
|
WO2018204717A1
(en)
|
2017-05-03 |
2018-11-08 |
Harpoon Therapeutics, Inc. |
Compositions and methods for adoptive cell therapies
|
|
BR112019023855B1
(pt)
|
2017-05-12 |
2021-11-30 |
Harpoon Therapeutics, Inc |
Proteínas de ligação à mesotelina
|
|
CN115028727A
(zh)
|
2017-05-12 |
2022-09-09 |
哈普恩治疗公司 |
靶向msln的三特异性蛋白质及使用方法
|
|
US20200270362A1
(en)
|
2017-05-12 |
2020-08-27 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
TWI843344B
(zh)
|
2017-06-02 |
2024-05-21 |
美商輝瑞大藥廠 |
對ｆｌｔ３具特異性之抗體及其用途
|
|
KR102677225B1
(ko)
|
2017-07-10 |
2024-06-24 |
이나뜨 파르마 에스.에이. |
Siglec-9 중화 항체
|
|
WO2019011852A1
(en)
|
2017-07-10 |
2019-01-17 |
Innate Pharma |
POLYTHERAPY USING ANTIBODY AGAINST SIGLEC-9 HUMAN AND ANTIBODY AGAINST NKG2A HUMAN FOR THE TREATMENT OF CANCER
|
|
JP7150820B2
(ja)
|
2017-08-01 |
2022-10-11 |
メディミューン，エルエルシー |
Ｂｃｍａモノクローナル抗体薬剤コンジュゲート
|
|
JP2019052753A
(ja)
|
2017-09-15 |
2019-04-04 |
日本電産株式会社 |
変速機及びアクチュエータ
|
|
JP7084990B2
(ja)
|
2017-10-13 |
2022-06-15 |
ハープーン セラピューティクス，インク． |
三重特異性タンパク質と使用方法
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
US11564946B2
(en)
|
2017-11-01 |
2023-01-31 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
WO2019136305A1
(en)
|
2018-01-04 |
2019-07-11 |
Neumedicines Inc. |
Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer
|
|
EP3759146A1
(en)
|
2018-03-02 |
2021-01-06 |
CDR-Life AG |
Trispecific antigen binding proteins
|
|
US20210284728A1
(en)
|
2018-05-14 |
2021-09-16 |
Harpoon Therapeutics, Inc. |
Dual binding moiety
|
|
WO2019222283A1
(en)
|
2018-05-14 |
2019-11-21 |
Harpoon Therapeutics, Inc. |
Binding moiety for conditional activation of immunoglobulin molecules
|
|
US20210269530A1
(en)
|
2018-05-14 |
2021-09-02 |
Harpoon Therapeutics, Inc. |
Conditionally activated binding protein comprising a sterically occluded target binding domain
|
|
KR20250151605A
(ko)
|
2018-06-01 |
2025-10-21 |
노파르티스 아게 |
Bcma에 대한 결합 분자 및 이의 용도
|
|
EP3806889A4
(en)
|
2018-06-18 |
2022-07-13 |
Anwita Biosciences, Inc. |
CYTOKI FUSION PROTEINS AND USES THEREOF
|
|
CN113226324B
(zh)
|
2018-09-11 |
2024-12-31 |
Iteos比利时公司 |
作为a2a抑制剂的硫代氨基甲酸酯衍生物、其药物组合物以及与抗癌剂的组合
|
|
US20210355219A1
(en)
|
2018-09-21 |
2021-11-18 |
Harpoon Therapeutics, Inc. |
Conditionally activated target-binding molecules
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
US20220054544A1
(en)
|
2018-09-21 |
2022-02-24 |
Harpoon Therapeutics, Inc. |
Conditionally active receptors
|
|
CN113286817B
(zh)
|
2018-09-25 |
2025-01-28 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
WO2020092792A2
(en)
|
2018-10-31 |
2020-05-07 |
Oncotracker, Inc. |
Method of enhancing immune-based therapy
|
|
WO2020097403A1
(en)
|
2018-11-08 |
2020-05-14 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and t cell modulation
|
|
CN109593786A
(zh)
|
2019-01-09 |
2019-04-09 |
上海怡豪生物科技有限公司 |
联合EpCAM和MSLN单链抗体的双靶点CAR载体及其构建方法和在乳腺癌应用
|
|
AU2020231391A1
(en)
|
2019-03-05 |
2021-10-28 |
Takeda Pharmaceutical Company Limited |
Conditionally activated binding proteins containing Fc regions and moieties targeting tumor antigens
|
|
US12516128B2
(en)
|
2019-05-14 |
2026-01-06 |
Harpoon Therapeutics, Inc. |
EpCAM binding proteins and methods of use
|
|
EP3983439A1
(en)
|
2019-06-13 |
2022-04-20 |
CytomX Therapeutics, Inc. |
Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer
|
|
AU2020307471A1
(en)
|
2019-06-24 |
2022-01-27 |
Novartis Ag |
Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen
|
|
MX2021015452A
(es)
|
2019-06-25 |
2022-02-11 |
Gilead Sciences Inc |
Proteinas de fusion flt3l-fc y metodos de uso.
|
|
WO2021097060A1
(en)
|
2019-11-13 |
2021-05-20 |
Harpoon Therapeutics, Inc. |
Pro immune modulating molecule comprising a clustering moiety
|
|
IL295448A
(en)
|
2020-02-21 |
2022-10-01 |
Harpoon Therapeutics Inc |
flt3 binding proteins and methods of use
|
|
WO2021231434A1
(en)
|
2020-05-12 |
2021-11-18 |
Harpoon Therapeutics, Inc. |
Psma targeting tritacs and methods of use
|
|
WO2022032006A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il2rb binding molecules and methods of use
|
|
US12077594B2
(en)
|
2020-08-05 |
2024-09-03 |
Synthekine, Inc. |
IL2RG binding molecules and methods of use
|
|
US20240228656A1
(en)
|
2020-11-06 |
2024-07-11 |
Harpoon Therapeutics, Inc. |
Epcam targeting trispecific protein for treatment of cancer
|
|
EP4304728A4
(en)
|
2021-03-09 |
2025-08-20 |
Harpoon Therapeutics Inc |
COMBINATION THERAPY WITH IMMUNE CELL CONTACT PROTEINS AND IMMUNOMODULATORS
|
|
WO2022212732A1
(en)
|
2021-04-01 |
2022-10-06 |
Harpoon Therapeutics, Inc. |
Psma targeting tritacs and methods of use
|
|
WO2022256498A1
(en)
|
2021-06-03 |
2022-12-08 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
EP4347637A4
(en)
|
2021-06-03 |
2025-04-16 |
Harpoon Therapeutics, Inc. |
DLL3 as a target for trispecific proteins and methods of use
|
|
CA3220878A1
(en)
|
2021-06-03 |
2022-12-08 |
Harpoon Therapeutics, Inc. |
Bcma targeting trispecific proteins and methods of use
|
|
AU2022297538A1
(en)
|
2021-06-25 |
2024-01-25 |
Harpoon Therapeutics, Inc. |
Extended-release immune cell engaging proteins and methods of treatment
|
|
WO2023064945A2
(en)
|
2021-10-15 |
2023-04-20 |
Harpoon Therapeutics, Inc. |
Conditional activation of immunoglobulin molecules
|